Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$77,190.00-1.30%ETH$2,459.99-0.30%GOLD$4,358.50-2.29%OIL$103.93+8.20%
Smart Investors Daily
NA

NASDAQ · NAMSW

NewAmsterdam Pharma Company N.V.

Healthcare · Biotechnology

$11.78

Down-$0.68 (-5.77%)

Updated Sep 10, 2026, 9:36 PM

SID Score

3.3/10

Composite research score

Smart Money

54/100

Neutral

Market cap
2.82B
P/E ratio
-19.49
Dividend yield
0.00%
52-week range
$11.78 – $30.45
Volume
1.2K
Avg. volume
3.52K

Price performance

NAMSW price history

1M range · 8 trading sessions · Daily adjusted prices

NAMSW closed at $11.78 after 8 trading sessions, down 30.67% for the selected period.

Last close
$11.78
Period change
-30.67%
Period low
$11.78
Period high
$16.99
Daily close
View OHLC price history
NAMSW OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 9, 2026$12.52$12.52$11.78$11.781.2K
Sep 8, 2026$12.62$13.26$12.62$13.26369
Sep 4, 2026$13.88$13.88$13.88$13.88102
Sep 3, 2026$13.05$14.49$13.05$14.446.83K
Aug 20, 2026$16.51$16.51$16.51$16.51211
Aug 18, 2026$16.00$16.00$15.98$16.0015.01K
Aug 17, 2026$17.46$17.46$15.0101$16.0016.44K
Aug 12, 2026$17.50$17.5001$16.72$16.995.61K

Latest NAMSW news

The latest Smart Investors Daily articles mentioning NAMSW.

Stock researchCompany · Overview

NAMSW research

Overview

Company profile and research snapshot.

Company profile

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 3, 2026

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NAARDEN, The Netherlands and MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’

Yahoo · Sep 2, 2026

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September

NAARDEN, The Netherlands and MIAMI, Sept. 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the

Yahoo · Aug 26, 2026

NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026

NAARDEN, The Netherlands and MIAMI, Aug. 26, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present data from its obicetrapib de

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By